(CercleFinance.com) – AbbVie publishes adjusted EPS of $2.79 for the fourth quarter of 2023, down 22.5%, with an adjusted operating margin of 43.8% for revenue of $14.3 billion, down 5.4%.
The health group specifies that the growth in its revenues in neuroscience (+22.6%) and aesthetics (+6.4%) was more than offset by the decline in its revenues in immunology (-12.3%). and in oncology (-7.4%).
Thus showing an adjusted EPS down 19.3% to $11.11 for the whole of 2023, AbbVie expects $11.05 to $11.25 for 2024 and reaffirms its forecast of annual revenue growth ‘in the high single-digit range’ by 2029.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
